Dear Editor,
The 2022 mpox (monkeypox) outbreak was first sparked in Europe, and subsequently spread to Americas. There are several unique features of the 2022 outbreaks in non-endemic countries. Men who have sex with men (MSM) are the main affected population, and the transmission is primarily driven by sex-related intimate contacts. However, there appears substantial disparities in the dynamics of the epidemic evolvement between Europe and Americas.
The reproduction number (R) is a hallmark of epidemic transmission dynamics. We estimated the time-varying reproduction number Rt for the 2022 mpox outbreaks in Europe and Americas, respectively. At the early stage, the Rt value was higher in Europe compared to that in Americas. However, since 27 June 2022, the Rt value in Americas rapidly surpassed that in Europe, which corresponded to the rapid escalation of reported cases, particularly in the USA. Although the reproduction numbers gradually declined in both regions, there remains a substantial gap (Fig. 1A). For example, the average reproduction number in Americas is 0.82 (95% CI 0.76–0.88), while that of Europe is only 0.62 (95% CI 0.44–0.84) during December 2022. This is in line with the confirmed cases of about 2000 and 160 in Americas and Europe in that month, respectively [1,2].
We postulate that there are several possible factors contributing to these disparities in transmission dynamics, including the levels of awareness, demographic characteristics and countermeasure implementation. As shown by the age pyramid, a larger proportion of reported cases in Americas compared to Europe (73.4% versus 61.3%) are in the group of under 40 years old (Fig. 1B). This young group of infected patients with high sexual activity may sustain the transmission. Secondly, sexual orientation of the majority (96.0%) of European cases is MSM, whereas this proportion in Americas is 77.9% (Fig. 1C). This suggests that the scale of spillover to other populations is likely larger in Americas. This may also explain that, despite a 50% reduction of sex partners or one-time sexual encounters in the USA [3], the outbreak remains not fully controlled. The awareness of mpox is presumably much lower in the general compared to high-risk populations, and transmission in general community would pose additional challenges in containing the outbreak.
The smallpox vaccines are currently being used for preventing mpox spread through ring vaccination or vaccinating high-risk populations. Although it is assumed to have 85% efficacy in cross-protection against mpox [4], there are emerging concerns regarding the actual efficacy which requires further assessment in particular in at-risk populations [5]. Furthermore, the accessibility to the vaccines varies tremendously even within the American region. The US government has prioritized to vaccinate 1.7 million people who are considered at highest risk, whereas the accessibility to these vaccines is very limited in Latin America.
Encouragingly, the reproduction number has gradually declined and is currently (January 2023) below one in Americas. However, there remains several contemporary challenges in containing the outbreak. Because of the heterogeneous capacity across different countries, Americas need to move more cohesively and quickly in responding to this crisis.
Conflict of interest disclosures
None reported.
Handling Editor: Patricia Schlagenhauf
Contributor Information
Chunbing Bao, Email: bcb@sdu.edu.cn.
Qiuwei Pan, Email: q.pan@erasmusmc.nl.
References
- 1.WHO 2022 monkeypox outbreak: global trends. 2022. https://worldhealthorg.shinyapps.io
- 2.CDC U.S. Monkeypox case trends reported to CDC. 2022. https://www.cdc.gov/poxvirus/monkeypox/response/2022/mpx-trends.html
- 3.CDC Impact of monkeypox outbreak on select behaviors. 2022. https://www.cdc.gov/poxvirus/monkeypox/response/2022/amis-select-behaviors.html
- 4.CDC. Monkeypox and smallpox vaccine guidance. 2022. https://www.cdc.gov/poxvirus/monkeypox/clinicians/smallpox-vaccine.html [Google Scholar]
- 5.Zaeck L.M., Lamers M.M., Verstrepen B.E., et al. Low levels of monkeypox virus neutralizing antibodies after MVA-BN vaccination in healthy individuals. Nat Med. 2023;29(1):270–278. doi: 10.1038/s41591-022-02090-w. [DOI] [PMC free article] [PubMed] [Google Scholar]